Close

IGRP

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Type 1 diabetes (T1D) in both humans and nonobese diabetic (NOD) mice is a chronic autoimmune disease that results from destruction of pancreatic β cells by CD4+ and CD8+ T cells targeting many antigens. A large fraction of the islet-associated CD8+ cells in NOD mice recognize the mimotopes NRP-A7 and -V7 in the context of the MHC molecule Kd. These T cells are diabetogenic, target a peptide from islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP 206-214, similar to NRP-A7 and -V7), and circulate in the blood, particularly as clinical disease nears. Another important feature of the diabetogenic CD8+ response is that it involves recognition, by smaller T cell pools, of many other IGRP epitopes and epitopes in other, even ubiquitous, autoantigens, such as dystrophia myotonica kinase (DMK). The polyspecificity of this T cell response is compounded by the fact that individual specificities harbor clones engaging pMHC over a range of avidities, the strength of which correlates with pathogenic potential.
  • TCR Vector Products

  • TCR Cell Products

  • TCR Viral Particles

Loading...
  • TCR Clone:
  • Host Species:
  • Epitope:
  • Allele:
  • Vector Type:
CAT Product Name Target Species TCR Clone Host Species Epitope Allele Vector Type Inquiry & Datasheet
TCR-YC0550 Mouse anti-IGRP T cell receptor (17.6α-8.3β), pCDTCR1 17.6α-8.3β Mouse KYNKANAFL H2-Kᵈ Lentiviral vector   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.